Global Blood Takes HOPE In Sickle Cell After Pulmonary Fibrosis Failure
Executive Summary
GBT440 is not efficacious enough in studies of idiopathic pulmonary fibrosis, but the drug was well-tolerated at twice the exposure in the treatment of sickle cell disease, the drug's lead indication.
You may also be interested in...
ASH Preview: Practice-Changing Darzalex And Imbruvica, Advances In Beta-Thalassemia And More
Late-breaker presentations for Darzalex in multiple myeloma and Imbruvica in CLL will showcase "practice-changing" results in front-line settings. Other highlights include new treatments for beta-thalassemia, such as Acceleron's and Celgene's luspatercept.
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
Public Company Edition: Denali launched this year's largest biopharma IPO. Also, Valeant sold notes to retire older debt, while bluebird, Blueprint and others capitalized on data presented at ASH.
Is Anemic Growth Sending Novo Nordisk After Global Blood Therapeutics?
Once high-flying Novo Nordisk has been sending out M&A signals as it seeks a solution to weak growth, so analysts aren't surprised to see the Danish diabetes giant stalking US-based Global Blood Therapeutics.